European Biotech Licensing Transactions

Case Study: European Biotech Licensing Transactions

Why PharmaVentures?

PharmaVentures was chosen because its experience in valuing clinical development assets, marketing these and supporting the negotiations leading up to the closure of licensing deals.

The Biotech Licensing Challenge

A European biotech needed to licence a clinical phase compound to treat a CNS disease.

The Solution

PharmaVentures conducted a compound valuation (bottom-up and bench marking using PharmaDeals Agreement s® data) providing the basis for future negotiations. PharmaVentures also carried out a thorough company screening and evaluation assessment to identify and prioritise potential licensees. Following the screening, within the space of a month PharmaVentures’ transaction team approached all the target companies with a carefully constructed value proposition using a non-confidential information package.

PharmaVentures managed the exchange of Confidential Disclosure Agreements followed by the facilitation of meetings leading to the exchange of confidential data presentations. PharmaVentures also set up and managed a confidential data room.

Partner / Product / Technology Screening

Case Study: Partner/ Product/ Technology Screening

The Challenge

A medium sized specialty pharma company was looking to expand its pipeline of product candidates using innovative drug delivery technologies. Having obtained funds for expansion the client wanted to screen out the most attractive products matching their core technology competencies and target markets.

The Solution

PharmaVentures designed a study combining primary and secondary research to assess unmet medical needs that the core technology could service as well as map out the competitive landscape in R&D to see the expected market shares of competitors and the clients potential products.

With the research highlighting key drivers for new technologies, PharmaVentures selected 15 product opportunities for in-licensing or in-house development with detailed evaluation of probable risks and returns.